[X] Close
You are about to erase all the values you have customized, search history, page format, etc.
Click here to RESET all values       Click here to GO BACK without resetting any value
Items 1 to 25 of about 25
1. Yoshida C, Takeuchi M: Histiocytic sarcoma: identification of its histiocytic origin using immunohistochemistry. Intern Med; 2008;47(3):165-9

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Histiocytic sarcoma: identification of its histiocytic origin using immunohistochemistry.
  • We describe a 56-year-old woman with histiocytic sarcoma involving the bone marrow.
  • The patient received multi-agent chemotherapy and is living at 22 months after diagnosis without recurrence.
  • Histiocytic sarcoma is an exceedingly rare hematopoietic neoplasm and the prognosis is poor due to its rapid progression, widespread disease and poor response to therapy.
  • It is important to recognize this rare neoplasm and to confirm the diagnosis using specific immunohistochemical markers.
  • [MeSH-major] Bone Marrow Neoplasms / diagnosis. Histiocytic Sarcoma / diagnosis

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18239326.001).
  • [ISSN] 1349-7235
  • [Journal-full-title] Internal medicine (Tokyo, Japan)
  • [ISO-abbreviation] Intern. Med.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Japan
  •  go-up   go-down


2. Skorupski KA, Clifford CA, Paoloni MC, Lara-Garcia A, Barber L, Kent MS, LeBlanc AK, Sabhlok A, Mauldin EA, Shofer FS, Couto CG, Sørenmo KU: CCNU for the treatment of dogs with histiocytic sarcoma. J Vet Intern Med; 2007 Jan-Feb;21(1):121-6
Hazardous Substances Data Bank. LOMUSTINE .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] CCNU for the treatment of dogs with histiocytic sarcoma.
  • BACKGROUND: Histiocytic sarcoma is an aggressive neoplasm of dendritic cells that carries a grave prognosis.
  • The efficacy of chemotherapy against this disease is unknown.
  • The purpose of this study was to determine the efficacy of 1-(2-chloroethyl)-3-cyclohexyl-1-nitrosourea (CCNU) in dogs with incompletely resected or metastatic histiocytic sarcoma, to describe the clinical characteristics of these dogs, and to identify factors affecting prognosis.
  • HYPOTHESIS: Our hypothesis is that CCNU has activity against canine histiocytic sarcoma and can improve survival in dogs with advanced disease.
  • ANIMALS: Included in analysis are dogs diagnosed with histiocytic sarcoma who had gross measurable or residual microscopic disease and who received CCNU.
  • Available biopsy samples were tested with an antibody against CD18 when possible to confirm the diagnosis of histiocytic sarcoma.
  • Treatment with CCNU at 60 to 90 mg/m2 resulted in an overall response rate of 46% in the 56 dogs with gross measurable disease.
  • CONCLUSIONS AND CLINICAL IMPORTANCE: Results suggest that CCNU is active against canine histiocytic sarcoma and may be useful in the treatment of dogs without negative prognostic factors.

  • MedlinePlus Health Information. consumer health - Cancer Chemotherapy.
  • MedlinePlus Health Information. consumer health - Soft Tissue Sarcoma.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17338159.001).
  • [ISSN] 0891-6640
  • [Journal-full-title] Journal of veterinary internal medicine
  • [ISO-abbreviation] J. Vet. Intern. Med.
  • [Language] ENG
  • [Publication-type] Journal Article; Multicenter Study; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antineoplastic Agents; 7BRF0Z81KG / Lomustine
  •  go-up   go-down


3. Saint-Marc O, Pozzo A, Cohen C, Le Tortorec S, Potier P, Berland B: [Gastric interdigitating reticulum cell sarcoma: unusual presentation of a histiocytic tumor]. Gastroenterol Clin Biol; 2002 May;26(5):526-8
Hazardous Substances Data Bank. METHYLPREDNISOLONE .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Gastric interdigitating reticulum cell sarcoma: unusual presentation of a histiocytic tumor].
  • Histiocytic sarcoma, proliferation arising from immunoregulatory effector system cells, is a very rare and recently recognized tumor.
  • Diagnosis is based on immunohistochemical and molecular genetic study, which allows to distinguish histiocytic sarcoma from lymphocytic proliferation, such as non-Hodgkin's lymphoma.
  • We report the case of a gastric interdigitating reticulum cell sarcoma, treated by resection and chemotherapy.
  • We review here clinical, histological, immunohistochemical and genotypic features of histiocytic tumors of the digestive tract.
  • [MeSH-minor] Antigens, CD / analysis. Antigens, Neoplasm / analysis. Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Biopsy. Cisplatin / therapeutic use. Cytarabine / therapeutic use. Diagnosis, Differential. Etoposide / therapeutic use. Gastrectomy. Humans. Immunohistochemistry. Male. Methylprednisolone / therapeutic use. Middle Aged

  • MedlinePlus Health Information. consumer health - Soft Tissue Sarcoma.
  • MedlinePlus Health Information. consumer health - Stomach Cancer.
  • Hazardous Substances Data Bank. CYTARABINE .
  • Hazardous Substances Data Bank. CIS-DIAMINEDICHLOROPLATINUM .
  • Hazardous Substances Data Bank. ETOPOSIDE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 12122368.001).
  • [ISSN] 0399-8320
  • [Journal-full-title] Gastroentérologie clinique et biologique
  • [ISO-abbreviation] Gastroenterol. Clin. Biol.
  • [Language] fre
  • [Publication-type] Case Reports; English Abstract; Journal Article
  • [Publication-country] France
  • [Chemical-registry-number] 0 / Antigens, CD; 0 / Antigens, Neoplasm; 04079A1RDZ / Cytarabine; 6PLQ3CP4P3 / Etoposide; Q20Q21Q62J / Cisplatin; X4W7ZR7023 / Methylprednisolone; ESAP protocol
  •  go-up   go-down


Advertisement
4. Abidi MH, Tove I, Ibrahim RB, Maria D, Peres E: Thalidomide for the treatment of histiocytic sarcoma after hematopoietic stem cell transplant. Am J Hematol; 2007 Oct;82(10):932-3
Hazardous Substances Data Bank. VINCRISTINE .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Thalidomide for the treatment of histiocytic sarcoma after hematopoietic stem cell transplant.
  • Histiocytic sarcoma (HS) is a rare neoplasm of uncertain etiology.
  • Thalidomide is a promising agent that may exert a therapeutic benefit in HS.
  • She underwent multi-agent chemotherapy followed by matched unrelated hematopoietic stem cell transplant.
  • Her disease recurred and thalidomide therapy was started, with her overall disease burden significantly reduced as measured radiographically.
  • [MeSH-major] Angiogenesis Inhibitors / therapeutic use. Hematopoietic Stem Cell Transplantation. Histiocytes / pathology. Retroperitoneal Neoplasms / drug therapy. Sarcoma / drug therapy. Thalidomide / therapeutic use
  • [MeSH-minor] Antineoplastic Combined Chemotherapy Protocols / administration & dosage. Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Cisplatin / administration & dosage. Combined Modality Therapy. Cyclophosphamide / administration & dosage. Cytarabine / administration & dosage. Dexamethasone / administration & dosage. Disease Progression. Doxorubicin / administration & dosage. Etoposide / administration & dosage. Female. Humans. Middle Aged. Prednisone / administration & dosage. Vincristine / administration & dosage

  • MedlinePlus Health Information. consumer health - Soft Tissue Sarcoma.
  • COS Scholar Universe. author profiles.
  • Hazardous Substances Data Bank. CYTARABINE .
  • Hazardous Substances Data Bank. CIS-DIAMINEDICHLOROPLATINUM .
  • Hazardous Substances Data Bank. DOXORUBICIN .
  • Hazardous Substances Data Bank. ETOPOSIDE .
  • Hazardous Substances Data Bank. DEXAMETHASONE .
  • Hazardous Substances Data Bank. CYCLOPHOSPHAMIDE .
  • Hazardous Substances Data Bank. THALIDOMIDE .
  • Hazardous Substances Data Bank. PREDNISONE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17617785.001).
  • [ISSN] 0361-8609
  • [Journal-full-title] American journal of hematology
  • [ISO-abbreviation] Am. J. Hematol.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Angiogenesis Inhibitors; 04079A1RDZ / Cytarabine; 4Z8R6ORS6L / Thalidomide; 5J49Q6B70F / Vincristine; 6PLQ3CP4P3 / Etoposide; 7S5I7G3JQL / Dexamethasone; 80168379AG / Doxorubicin; 8N3DW7272P / Cyclophosphamide; Q20Q21Q62J / Cisplatin; VB0R961HZT / Prednisone; DHAP protocol; EPOCH protocol
  •  go-up   go-down


5. Soriano AO, Thompson MA, Admirand JH, Fayad LE, Rodriguez AM, Romaguera JE, Hagemeister FB, Pro B: Follicular dendritic cell sarcoma: a report of 14 cases and a review of the literature. Am J Hematol; 2007 Aug;82(8):725-8
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Follicular dendritic cell sarcomas (FDCS) are grouped with the histiocytic and dendritic cell neoplasms.
  • The natural history and response to different treatments have not been well established.
  • Information on initial treatment was available in 11 patients, which included surgery alone in one patient, surgery and radiation in two, surgery and chemotherapy in one, chemotherapy alone in three, chemotherapy and radiation in one, surgery followed by radiation and chemotherapy in three patients.
  • In eight patients the initial chemotherapy regimen was cyclophosphamide, doxorubicin, vincristine, and prednisone.
  • Follicular sarcoma is an aggressive neoplasm.
  • Although most of the patients initially responded to treatment, the majority of them (81%) relapsed.
  • A better understanding of the biology of FDCS could guide our efforts in the development of new treatment modalities for this rare disease.
  • [MeSH-minor] Adult. Aged. Female. Humans. Male. Middle Aged. Neoplasm Staging. Treatment Outcome

  • MedlinePlus Health Information. consumer health - Soft Tissue Sarcoma.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17373675.001).
  • [ISSN] 0361-8609
  • [Journal-full-title] American journal of hematology
  • [ISO-abbreviation] Am. J. Hematol.
  • [Language] eng
  • [Grant] United States / NCI NIH HHS / CA / CA16672
  • [Publication-type] Case Reports; Journal Article; Research Support, N.I.H., Extramural; Review
  • [Publication-country] United States
  • [Number-of-references] 18
  •  go-up   go-down


6. Orsey A, Paessler M, Lange BJ, Nichols KE: Central nervous system juvenile xanthogranuloma with malignant transformation. Pediatr Blood Cancer; 2008 Apr;50(4):927-30
Hazardous Substances Data Bank. DEXAMETHASONE .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Juvenile xanthogranuloma (JXG) is a rare histiocytic disorder that typically manifests in the skin.
  • Here, we describe a patient with JXG diffusely involving the central nervous system (CNS), whose disease responded to therapy but subsequently underwent dissemination to the peritoneum and bone marrow.
  • Repeat biopsy at dissemination revealed pleomorphic histiocytes with tetraploidy, suggesting evolution to a clonal histiocytic neoplasm.
  • Despite further chemotherapy, the patient died of disease progression.
  • [MeSH-major] Brain Neoplasms / physiopathology. Brain Neoplasms / therapy. Histiocytic Sarcoma / pathology. Xanthogranuloma, Juvenile / physiopathology. Xanthogranuloma, Juvenile / therapy
  • [MeSH-minor] Anti-Inflammatory Agents / therapeutic use. Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Brain Diseases / pathology. Child. Cladribine / therapeutic use. Dexamethasone / therapeutic use. Diagnosis, Differential. Disease Progression. Fatal Outcome. Humans. Immunohistochemistry. In Situ Hybridization, Fluorescence. Magnetic Resonance Imaging. Male. Pseudotumor Cerebri / pathology. Radiotherapy


7. Hayase E, Kurosawa M, Yonezumi M, Suzuki S, Suzuki H: Aggressive sporadic histiocytic sarcoma with immunoglobulin heavy chain gene rearrangement and t(14;18). Int J Hematol; 2010 Nov;92(4):659-63

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Aggressive sporadic histiocytic sarcoma with immunoglobulin heavy chain gene rearrangement and t(14;18).
  • Histiocytic sarcoma (HS) is a rare but aggressive malignant neoplasm of histiocytic lineage with a poor prognosis.
  • HS was diagnosed according to morphologic and immunohistochemical features observed on biopsy of the left inguinal lymph node.
  • The tumor demonstrated a clonal immunoglobulin heavy chain gene rearrangement and a clonal cytogenetic abnormality including t(14;18) which was confirmed by fluorescence in situ hybridization analysis showing the IgH/BCL2 fusion gene.
  • Positron emission tomography showed disseminated areas of increased 18F-fluorodeoxyglucose uptake in multiple lymph nodes, the liver, spleen, both lungs, both kidneys, and many bony sites.
  • The patient received localized irradiation therapy followed by chemotherapy, she failed to respond and died of the disease progression.
  • [MeSH-major] Chromosomes, Human, Pair 14 / genetics. Chromosomes, Human, Pair 18 / genetics. Gene Rearrangement. Genes, Immunoglobulin Heavy Chain. Histiocytic Sarcoma / genetics. Translocation, Genetic

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Nat Immunol. 2007 May;8(5):463-70 [17440452.001]
  • [Cites] Nature. 2007 Sep 27;449(7161):473-7 [17851532.001]
  • [Cites] Blood. 2003 Mar 1;101(5):1950-5 [12406913.001]
  • [Cites] Am J Hematol. 2007 Oct;82(10):932-3 [17617785.001]
  • [Cites] Histopathology. 2002 Jul;41(1):1-29 [12121233.001]
  • [Cites] Am J Surg Pathol. 1996 Nov;20(11):1406-11 [8898846.001]
  • [Cites] Am J Surg Pathol. 2009 Jun;33(6):863-73 [19145200.001]
  • [Cites] Ann Nucl Med. 2008 Oct;22(8):715-7 [18982475.001]
  • [Cites] Am J Surg Pathol. 2005 May;29(5):617-24 [15832085.001]
  • [Cites] Mod Pathol. 2005 May;18(5):693-704 [15696128.001]
  • [Cites] Diagn Pathol. 2007 Feb 26;2:7 [17324277.001]
  • [Cites] Int J Hematol. 2009 May;89(4):529-32 [19343479.001]
  • [Cites] Blood. 2008 Jun 15;111(12):5433-9 [18272816.001]
  • [Cites] Leuk Lymphoma. 2010 May;51(5):802-12 [20331331.001]
  • [Cites] Cancer. 1995 Aug 15;76(4):609-17 [8625154.001]
  • [Cites] Cell. 2004 May 28;117(5):663-76 [15163413.001]
  • [Cites] Pediatrics. 2005 Aug;116(2):e322-5 [16024682.001]
  • [Cites] Int J Hematol. 2004 Nov;80(4):365-9 [15615263.001]
  • [Cites] Intern Med. 2008;47(3):165-9 [18239326.001]
  • [Cites] Am J Surg Pathol. 2004 Sep;28(9):1133-44 [15316312.001]
  • [Cites] J Hematop. 2009 May 09;2(3):135-41 [19669194.001]
  • [Cites] Lancet Oncol. 2004 Apr;5(4):248-50 [15050956.001]
  • (PMID = 20976632.001).
  • [ISSN] 1865-3774
  • [Journal-full-title] International journal of hematology
  • [ISO-abbreviation] Int. J. Hematol.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Japan
  •  go-up   go-down


8. Rassnick KM, Moore AS, Russell DS, Northrup NC, Kristal O, Bailey DB, Flory AB, Kiselow MA, Intile JL: Phase II, open-label trial of single-agent CCNU in dogs with previously untreated histiocytic sarcoma. J Vet Intern Med; 2010 Nov-Dec;24(6):1528-31
Hazardous Substances Data Bank. LOMUSTINE .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Phase II, open-label trial of single-agent CCNU in dogs with previously untreated histiocytic sarcoma.
  • BACKGROUND: Histiocytic sarcoma (HS) is an aggressive neoplasm in dogs, and in most instances, the disease is localized, but not amenable to surgical removal, or is disseminated.
  • There have been no prospective studies to determine efficacy of single-agent chemotherapy in dogs with HS.
  • Evaluation of CCNU postoperatively for dogs with resectable localized HS and as part of combination therapy for tumors that are nonresectable or disseminated should be considered.

  • MedlinePlus Health Information. consumer health - Cancer Chemotherapy.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 21155191.001).
  • [ISSN] 0891-6640
  • [Journal-full-title] Journal of veterinary internal medicine
  • [ISO-abbreviation] J. Vet. Intern. Med.
  • [Language] ENG
  • [Publication-type] Clinical Trial, Phase II; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antineoplastic Agents; 7BRF0Z81KG / Lomustine
  •  go-up   go-down


9. Skorupski KA, Rodriguez CO, Krick EL, Clifford CA, Ward R, Kent MS: Long-term survival in dogs with localized histiocytic sarcoma treated with CCNU as an adjuvant to local therapy. Vet Comp Oncol; 2009 Jun;7(2):139-44
Hazardous Substances Data Bank. LOMUSTINE .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Long-term survival in dogs with localized histiocytic sarcoma treated with CCNU as an adjuvant to local therapy.
  • Histiocytic sarcoma (HS) is associated with a poor prognosis owing to the presence of metastasis at the time of diagnosis in most dogs.
  • Improved outcome has been reported in several dogs with localized HS following local therapy, however, distant metastasis occurs in 70-91% of dogs suggesting that adjuvant systemic therapy is necessary.
  • The purpose of this retrospective study was to describe clinical characteristics and outcome in dogs with localized HS treated with aggressive local therapy plus adjuvant CCNU chemotherapy.
  • Two dogs had local recurrence and eight dogs developed metastatic disease with a median time to relapse of 201 days in these 10 dogs.
  • The median survival time for all 16 dogs was 568 days.
  • These results support the recommendation for aggressive local therapy combined with adjuvant CCNU chemotherapy in dogs with localized HS.
  • [MeSH-major] Antineoplastic Agents / therapeutic use. Dog Diseases / drug therapy. Dog Diseases / mortality. Histiocytic Sarcoma / veterinary. Lomustine / therapeutic use
  • [MeSH-minor] Animals. Chemotherapy, Adjuvant / veterinary. Cohort Studies. Disease-Free Survival. Dogs. Female. Male. Neoplasm Metastasis. Prognosis. Retrospective Studies. Survival Rate. Time Factors. Treatment Outcome

  • MedlinePlus Health Information. consumer health - Cancer Chemotherapy.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19453368.001).
  • [ISSN] 1476-5829
  • [Journal-full-title] Veterinary and comparative oncology
  • [ISO-abbreviation] Vet Comp Oncol
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Antineoplastic Agents; 7BRF0Z81KG / Lomustine
  •  go-up   go-down


10. Hornick JL, Jaffe ES, Fletcher CD: Extranodal histiocytic sarcoma: clinicopathologic analysis of 14 cases of a rare epithelioid malignancy. Am J Surg Pathol; 2004 Sep;28(9):1133-44
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Extranodal histiocytic sarcoma: clinicopathologic analysis of 14 cases of a rare epithelioid malignancy.
  • Histiocytic sarcoma is a rare malignant neoplasm that occurs in lymph nodes, skin, and the gastrointestinal tract.
  • To characterize these tumors further, 14 extranodal histiocytic sarcomas were analyzed.
  • All patients presented with a solitary mass, ranging in size from 1.8 to 12 cm (median 6.8 cm).
  • Seven tumors arose in soft tissue (6 lower limb; 1 upper limb), 5 in the gastrointestinal tract (1 involving both stomach and colon, 1 ileum, 2 rectum, 1 anus), 1 in the nasal cavity, and 1 in the lung.
  • Six patients were treated with postoperative radiation and 7 with chemotherapy (CHOP or ProMACE-MOPP).
  • Two tumors recurred locally, and 5 patients developed distant spread: 3 to lymph nodes, 1 to lung, and 1 to bone.
  • Histiocytic sarcoma may arise primarily in soft tissue and shows reproducible histologic features, including abundant eosinophilic cytoplasm and a prominent inflammatory infiltrate.
  • Histiocytic sarcoma has the potential for an aggressive clinical course, most often with lymph node involvement.

  • Genetic Alliance. consumer health - Epithelioid Sarcoma.
  • MedlinePlus Health Information. consumer health - Soft Tissue Sarcoma.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15316312.001).
  • [ISSN] 0147-5185
  • [Journal-full-title] The American journal of surgical pathology
  • [ISO-abbreviation] Am. J. Surg. Pathol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


11. Paba V, Quarto M, Varriale L, Crescenzi E, Palumbo G: Photo-activation of hypericin with low doses of light promotes apparent photo-resistance in human histiocytic lymphoma U937 cells. J Photochem Photobiol B; 2001 Jul;60(2-3):87-96
Hazardous Substances Data Bank. PERYLENE .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Photo-activation of hypericin with low doses of light promotes apparent photo-resistance in human histiocytic lymphoma U937 cells.
  • We have observed that exposure of U937 cells, pre-incubated for 18 h with 0.2 microM hypericin, to 599 nm laser radiation with a fluence of 2.5 J/cm(2) renders them insensitive to higher light doses.
  • In fact, pre-sensitized cells appear to be fully resistant to light doses that normally determine massive cellular apoptosis in experimental photo-dynamic therapy.
  • [MeSH-major] Apoptosis / drug effects. Perylene / analogs & derivatives. Perylene / pharmacology. Perylene / radiation effects. Phototherapy
  • [MeSH-minor] Cell Death / drug effects. Cell Death / radiation effects. Dose-Response Relationship, Radiation. Drug Resistance, Neoplasm. HSP70 Heat-Shock Proteins / drug effects. HSP70 Heat-Shock Proteins / radiation effects. Humans. Necrosis. Radiation Injuries. U937 Cells / drug effects. U937 Cells / pathology

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 11470563.001).
  • [ISSN] 1011-1344
  • [Journal-full-title] Journal of photochemistry and photobiology. B, Biology
  • [ISO-abbreviation] J. Photochem. Photobiol. B, Biol.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Switzerland
  • [Chemical-registry-number] 0 / HSP70 Heat-Shock Proteins; 5QD5427UN7 / Perylene; 7V2F1075HD / hypericin
  •  go-up   go-down


12. Muramatsu Y, Hasegawa Y, Fukano H, Ogawa T, Namuba M, Mouri K, Fujimoto Y, Matsuura H, Takai Y, Mori M: Metallothionein immunoreactivity in head and neck carcinomas; special reference to clinical behaviors and chemotherapy responses. Anticancer Res; 2000 Jan-Feb;20(1A):257-64
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Metallothionein immunoreactivity in head and neck carcinomas; special reference to clinical behaviors and chemotherapy responses.
  • Metallothionein (MT), has selectively binding affinity for heavy metal ions and over expression of MT has a potential against resistance for CDDP anticancer agents and radiation treatment.
  • Histiocytic and fibrocytic cells in both peripheral and interstitial stromas were also not stained homogeneously.
  • [MeSH-major] Carcinoma, Squamous Cell / chemistry. Head and Neck Neoplasms / chemistry. Metallothionein / analysis. Neoplasm Proteins / analysis
  • [MeSH-minor] Adult. Aged. Antineoplastic Combined Chemotherapy Protocols / chemistry. Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Carboplatin / administration & dosage. Cell Differentiation. Chemotherapy, Adjuvant. Cisplatin / administration & dosage. Combined Modality Therapy. Drug Resistance, Neoplasm. Female. Fluorouracil / administration & dosage. Gingival Neoplasms / chemistry. Gingival Neoplasms / pathology. Gingival Neoplasms / therapy. Humans. Hypopharyngeal Neoplasms / chemistry. Hypopharyngeal Neoplasms / pathology. Hypopharyngeal Neoplasms / therapy. Lymphatic Metastasis. Male. Maxillary Sinus Neoplasms / chemistry. Maxillary Sinus Neoplasms / pathology. Maxillary Sinus Neoplasms / therapy. Middle Aged. Mouth Mucosa / chemistry. Tongue Neoplasms / chemistry. Tongue Neoplasms / pathology. Tongue Neoplasms / therapy. Treatment Outcome

  • MedlinePlus Health Information. consumer health - Head and Neck Cancer.
  • Hazardous Substances Data Bank. CIS-DIAMINEDICHLOROPLATINUM .
  • Hazardous Substances Data Bank. CARBOPLATIN .
  • Hazardous Substances Data Bank. FLUOROURACIL .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 10769664.001).
  • [ISSN] 0250-7005
  • [Journal-full-title] Anticancer research
  • [ISO-abbreviation] Anticancer Res.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] GREECE
  • [Chemical-registry-number] 0 / Neoplasm Proteins; 9038-94-2 / Metallothionein; BG3F62OND5 / Carboplatin; Q20Q21Q62J / Cisplatin; U3P01618RT / Fluorouracil
  •  go-up   go-down


13. Colovic N, Jurisic V, Colovic M: Malignant histiocytosis with central nervous system involvement and hepatic mucinous cystadenoma in a single patient with review of the literature. J BUON; 2007 Oct-Dec;12(4):539-42
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Malignant histiocytosis is a rare neoplasm of the reticuloendothelial system characterized by neoplastic proliferation of tissue histiocytes.
  • The therapy was switched to CHOP (cyclophosphamide, vincristine, doxorubicin, and prednisone) with disappearance of lymphadenopathy.
  • Two months after completion of 8 cycles of CHOP she experienced severe headaches, vomiting, loss of consciousness, and developed paraparesis.
  • The patient was then treated with intrathecal methotrexate, prednisolone and cytosine-arabinoside and systemic chemotherapy with etoposide and cyclophosphamide.
  • Her condition improved, she became conscious, her headache diminished, she became mobile but skin and nodal lesions reappeared along with extensive marrow histiocytic infiltration.
  • [MeSH-major] Brain Neoplasms / diagnosis. Histiocytic Sarcoma / diagnosis. Neoplasms, Second Primary / diagnosis


14. Lemos LB, Qu Z, Garg K, Papasozomenos S: Pseudoneoplastic proliferation of histiocytes with paclitaxel-induced ultrastructural changes in a mastectomy specimen. Ann Diagn Pathol; 2004 Oct;8(5):299-304
Hazardous Substances Data Bank. FLUOROURACIL .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • A 49-year-old Hispanic woman with a T4N1M0 infiltrating duct carcinoma of the left breast underwent four courses of FAC (doxorubicin 86 mg, 5-fluorouracil 860 mg, cyclophosphamide 86 mg, and dexamethasone 10 mg) adjuvant chemotherapy plus four courses of paclitaxel (Taxol; Bristol-Myers Squibb Oncology, Princeton, NJ) and subsequent mastectomy.
  • The tumor shrunk from 6.5 cm to 2.5 cm after the treatment.
  • The tumor showed typical chemotherapy changes and a massive proliferation of histiocytes that mimicked a neoplasm.
  • The histiocytic cells contained lamellar and coarse periodic acid-Schiff-positive material distending their cytoplasm and they were strongly positive for CD68 and negative for CD1a, pan keratin, and S-100.
  • [MeSH-major] Antineoplastic Agents, Phytogenic / therapeutic use. Breast Neoplasms / pathology. Carcinoma, Ductal, Breast / secondary. Histiocytes / ultrastructure. Mastectomy. Paclitaxel / therapeutic use
  • [MeSH-minor] Antineoplastic Combined Chemotherapy Protocols / administration & dosage. Biomarkers, Tumor. Cell Proliferation / drug effects. Chemotherapy, Adjuvant. Cyclophosphamide / administration & dosage. Doxorubicin / administration & dosage. Female. Fluorouracil / administration & dosage. Humans. Intermediate Filaments / drug effects. Intermediate Filaments / ultrastructure. Lymph Nodes / pathology. Lymphatic Metastasis. Mastectomy, Modified Radical. Middle Aged. Sentinel Lymph Node Biopsy. Tubulin / analysis

  • MedlinePlus Health Information. consumer health - Breast Cancer.
  • MedlinePlus Health Information. consumer health - Mastectomy.
  • COS Scholar Universe. author profiles.
  • Hazardous Substances Data Bank. DOXORUBICIN .
  • Hazardous Substances Data Bank. TAXOL .
  • Hazardous Substances Data Bank. CYCLOPHOSPHAMIDE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15494938.001).
  • [ISSN] 1092-9134
  • [Journal-full-title] Annals of diagnostic pathology
  • [ISO-abbreviation] Ann Diagn Pathol
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antineoplastic Agents, Phytogenic; 0 / Biomarkers, Tumor; 0 / Tubulin; 80168379AG / Doxorubicin; 8N3DW7272P / Cyclophosphamide; P88XT4IS4D / Paclitaxel; U3P01618RT / Fluorouracil; CAF protocol
  •  go-up   go-down


15. Sabo D, Bernd L, Buchner M, Treiber M, Wannenmacher M, Ewerbeck V, Parsch D: [Intraoperative extracorporeal irradiation and replantation in local treatment of primary malignant bone tumors]. Orthopade; 2003 Nov;32(11):1003-12
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Intraoperative extracorporeal irradiation and replantation in local treatment of primary malignant bone tumors].
  • In 13 patients with primary malignant bone tumors (10 Ewing's sarcoma, 1 parosteal osteosarcoma, 1 adamantinoma recurrence, and 1 MFH) local therapy was performed as intraoperative extracorporeal irradiation and replantation (IEIR) of the involved bone segment (5 tibia, 2 femur, and 6 pelvis).
  • Of the 13 patients (69%), 9 are alive at the time of the follow-up (5 CDF, 4 AWM(treated)) and 4 patients died of disease (DOD).
  • IEIR must be seen as an extraordinary reconstruction procedure in cases where established procedures such as endoprosthesis, biological reconstructions, or rotationplasties cannot be used or are refused by the patient.
  • [MeSH-minor] Adolescent. Adult. Aged. Ameloblastoma / drug therapy. Ameloblastoma / pathology. Ameloblastoma / radiotherapy. Ameloblastoma / surgery. Child, Preschool. Combined Modality Therapy. Female. Femoral Neoplasms / drug therapy. Femoral Neoplasms / pathology. Femoral Neoplasms / radiotherapy. Femoral Neoplasms / surgery. Follow-Up Studies. Histiocytic Sarcoma / drug therapy. Histiocytic Sarcoma / pathology. Histiocytic Sarcoma / radiotherapy. Histiocytic Sarcoma / surgery. Humans. Male. Neoadjuvant Therapy. Neoplasm Recurrence, Local / drug therapy. Neoplasm Recurrence, Local / pathology. Neoplasm Recurrence, Local / radiotherapy. Neoplasm Recurrence, Local / surgery. Neoplasm Staging. Osteosarcoma / drug therapy. Osteosarcoma / pathology. Osteosarcoma / radiotherapy. Osteosarcoma / surgery. Radiotherapy Dosage. Sarcoma, Ewing / drug therapy. Sarcoma, Ewing / pathology. Sarcoma, Ewing / radiotherapy. Sarcoma, Ewing / surgery. Tibia / pathology. Tibia / surgery

  • MedlinePlus Health Information. consumer health - Bone Cancer.
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Klin Padiatr. 1988 May-Jun;200(3):243-52 [3145357.001]
  • [Cites] J Bone Joint Surg Am. 1987 Apr;69(4):583-95 [2952660.001]
  • [Cites] Orthop Clin North Am. 1987 Apr;18(2):275-89 [3550576.001]
  • [Cites] Langenbecks Arch Surg. 2003 Jan;387(9-10):355-65 [12536331.001]
  • [Cites] Acta Orthop Scand. 1996 Dec;67(6):583-8 [9065072.001]
  • [Cites] Cancer. 1982 Aug 15;50(4):613-30 [7046906.001]
  • [Cites] Anticancer Res. 2002 Nov-Dec;22(6B):3685-90 [12552977.001]
  • [Cites] J Bone Joint Surg Am. 1995 Jan;77(1):54-64 [7822356.001]
  • [Cites] Cancer. 1976 Jan;37(1):1-11 [1082364.001]
  • [Cites] Z Orthop Ihre Grenzgeb. 1992 Jul-Aug;130(4):285-9 [1413973.001]
  • [Cites] J Bone Joint Surg Br. 1988 May;70(3):348-53 [3163694.001]
  • [Cites] J Orthop Res. 1985;3(4):389-404 [3906062.001]
  • [Cites] Cancer. 1983 Sep 15;52(6):1017-21 [6883269.001]
  • [Cites] Unfallchirurg. 1999 Jul;102(7):580-8 [10459306.001]
  • [Cites] Clin Orthop Relat Res. 1991 Sep;(270):223-30 [1884544.001]
  • [Cites] Int Orthop. 1998;22(1):32-6 [9580457.001]
  • [Cites] Int Orthop. 1997;21(5):283-90 [9476156.001]
  • [Cites] Acta Orthop Scand. 1988 Feb;59(1):34-8 [3128053.001]
  • [Cites] J Bone Joint Surg Br. 2000 Mar;82(2):276-82 [10755441.001]
  • [Cites] J Bone Joint Surg Am. 1986 Mar;68(3):362-9 [3456348.001]
  • [Cites] J Bone Joint Surg Am. 1991 Sep;73(8):1123-42 [1890115.001]
  • [Cites] Clin Orthop Relat Res. 1993 Jan;(286):241-6 [8425352.001]
  • [Cites] Clin Orthop Relat Res. 1999 Nov;(368):196-206 [10613169.001]
  • [Cites] Clin Orthop Relat Res. 1993 Oct;(295):226-38 [8403653.001]
  • [Cites] Clin Orthop Relat Res. 1990 Feb;(251):249-53 [2295182.001]
  • [Cites] Rev Chir Orthop Reparatrice Appar Mot. 1991;77(1):6-13 [1829244.001]
  • (PMID = 14615850.001).
  • [ISSN] 0085-4530
  • [Journal-full-title] Der Orthopade
  • [ISO-abbreviation] Orthopade
  • [Language] ger
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] Germany
  •  go-up   go-down


16. Bai CM, Yang T, Xü Y, Zhang W, Liu XL, Zhu YL, Chen SC, Shen T: [Clinical analysis of 32 primary intestinal non-Hodgkin's lymphoma]. Zhonghua Zhong Liu Za Zhi; 2006 Feb;28(2):142-4
Hazardous Substances Data Bank. VINCRISTINE .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • OBJECTIVE: To investigate the clinical and pathological features, optimal treatment and prognostic factors in primary intestinal non-Hodgkin's lymphoma.
  • METHODS: The clinical presentations, pathological features and therapeutic results of 32 primary intestinal non-Hodgkin's lymphoma were retrospectively analyzed.
  • Ten patients (31.2%) were diagnosed as T-cell lymphoma and one (3.1%) as histiocytic lymphoma.
  • Twenty-nine patients were treated initially by surgery with or without chemotherapy, 19 of them (59.4%) achieved complete response.
  • Most of the histological types are diffuse large B-cell type lymphoma.
  • Complete resection combined with chemotherapy may be the best effective approach for treatment of this disease.
  • [MeSH-minor] Adult. Antineoplastic Combined Chemotherapy Protocols / administration & dosage. Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Cyclophosphamide / administration & dosage. Doxorubicin / administration & dosage. Female. Follow-Up Studies. Humans. Lymphoma, B-Cell / drug therapy. Lymphoma, B-Cell / pathology. Lymphoma, B-Cell / surgery. Lymphoma, Large B-Cell, Diffuse / drug therapy. Lymphoma, Large B-Cell, Diffuse / pathology. Lymphoma, Large B-Cell, Diffuse / surgery. Male. Middle Aged. Neoplasm Staging. Prednisone / administration & dosage. Proportional Hazards Models. Remission Induction. Retrospective Studies. Survival Rate. Vincristine / administration & dosage

  • Hazardous Substances Data Bank. DOXORUBICIN .
  • Hazardous Substances Data Bank. CYCLOPHOSPHAMIDE .
  • Hazardous Substances Data Bank. PREDNISONE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16750023.001).
  • [ISSN] 0253-3766
  • [Journal-full-title] Zhonghua zhong liu za zhi [Chinese journal of oncology]
  • [ISO-abbreviation] Zhonghua Zhong Liu Za Zhi
  • [Language] chi
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] China
  • [Chemical-registry-number] 5J49Q6B70F / Vincristine; 80168379AG / Doxorubicin; 8N3DW7272P / Cyclophosphamide; VB0R961HZT / Prednisone; CHOP protocol
  •  go-up   go-down


17. Blum R, Seymour JF, Hicks RJ: Role of 18FDG-positron emission tomography scanning in the management of histiocytosis. Leuk Lymphoma; 2002 Nov;43(11):2155-7
Genetic Alliance. consumer health - Histiocytosis.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Role of 18FDG-positron emission tomography scanning in the management of histiocytosis.
  • Diagnostic evaluation of histiocytic malignancies often involves a range of imaging studies to characterize skeletal and extraskeletal sites of involvement.
  • We report two cases where this modality was positive and facilitated therapeutic monitoring.
  • [MeSH-major] Fluorodeoxyglucose F18. Histiocytosis / radionuclide imaging. Tomography, Emission-Computed
  • [MeSH-minor] Adolescent. Adult. Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Bone Neoplasms / diagnosis. Bone Neoplasms / drug therapy. Bone Neoplasms / radionuclide imaging. Disease Management. Histiocytosis, Langerhans-Cell / diagnosis. Histiocytosis, Langerhans-Cell / drug therapy. Histiocytosis, Langerhans-Cell / radionuclide imaging. Humans. Male. Neoplasm Staging / methods. Treatment Outcome

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 12533041.001).
  • [ISSN] 1042-8194
  • [Journal-full-title] Leukemia & lymphoma
  • [ISO-abbreviation] Leuk. Lymphoma
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] England
  • [Chemical-registry-number] 0Z5B2CJX4D / Fluorodeoxyglucose F18
  •  go-up   go-down


18. Kajiwara R, Goto H, Yanagimachi M, Kuroki F, Fujii H, Takahashi H, Yokota S: [Recurrent spontaneous regression of aleukemic leukemia cutis in a girl with acute monocytic leukemia]. Rinsho Ketsueki; 2006 Aug;47(8):764-9
MedlinePlus Health Information. consumer health - Leukemia.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Histological examination revealed partial infiltration of histiocytic cells in the skin lesion.
  • However, the diagnosis could not be made at that time.
  • At 9 and at 13 months old, appearances of exanthema similar to the previous time were combined with systemic fever, abnormal coagulation tests, and the marked increases of atypical lymphocytes in peripheral blood: however, these symptoms resolved spontaneously.
  • Complete remission was obtained with standard chemotherapy.
  • Six months after the therapy was completed, an extramedullary relapse occurred in the inguinal lymph nodes, which was successfully treated with allogeneic bone marrow transplantation from an HLA-matched unrelated donor, and the patient has been free of disease for two years after the transplantation.
  • [MeSH-major] Leukemia / diagnosis. Leukemia / etiology. Leukemia, Monocytic, Acute / complications. Neoplasm Regression, Spontaneous

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16986716.001).
  • [ISSN] 0485-1439
  • [Journal-full-title] [Rinshō ketsueki] The Japanese journal of clinical hematology
  • [ISO-abbreviation] Rinsho Ketsueki
  • [Language] jpn
  • [Publication-type] Case Reports; English Abstract; Journal Article
  • [Publication-country] Japan
  •  go-up   go-down


19. Govier SM: Principles of treatment for mast cell tumors. Clin Tech Small Anim Pract; 2003 May;18(2):103-6
NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Principles of treatment for mast cell tumors.
  • Surgery is the treatment of choice for solitary MCTs with no evidence of metastasis.
  • Reponses rates to chemotherapy, (partial response) as high as 78% have been reported, and preliminary evidence suggests that multiagent (prednisone and vinblastine) protocols may confer a higher response rate than single-agent therapy.
  • The more common form is the mastocytic form, and the less common is the histiocytic form.
  • As with dogs with cutaneous MCTs, surgery is the treatment of choice.
  • Little is known about the effectiveness of adjunctive chemotherapy options for cutaneous MCTs.
  • Adjunctive chemotherapy does not appear to increase survival times.
  • [MeSH-minor] Animals. Cats. Dogs. Neoplasm Staging / veterinary. Prognosis. Veterinary Medicine

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 12831070.001).
  • [ISSN] 1096-2867
  • [Journal-full-title] Clinical techniques in small animal practice
  • [ISO-abbreviation] Clin Tech Small Anim Pract
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] United States
  • [Number-of-references] 13
  •  go-up   go-down


20. Kiyohara T, Kumakiri M, Kobayashi H, Shimizu T, Ohkawara A, Ohnuki M: A case of intravascular large B-cell lymphoma mimicking erythema nodosum: the importance of multiple skin biopsies. J Cutan Pathol; 2000 Sep;27(8):413-8
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • The neoplastic cells are usually of B-cell origin, and rarely of T-cell or histiocytic origin.
  • The second biopsy revealed emboli of atypical lymphocytes within many of the dilated and proliferated vessels in the deep dermis and subcutaneous tissue.
  • Before the treatment, the size of the nodules decreased spontaneously by about 50% in one month and significantly in two months.
  • Although combination chemotherapy, which consisted of CHOP, brought her partial remission, she experienced neurological symptoms 6 months after the initial treatment and died of brain metastasis 9 months after the treatment.
  • 1) the first biopsy revealed non-specific findings compatible with erythema nodosum; and 2) before the treatment, the nodules regressed spontaneously.
  • [MeSH-major] Erythema Nodosum / diagnosis. Lymphoma, B-Cell / diagnosis. Lymphoma, Large B-Cell, Diffuse / diagnosis. Neoplasm Regression, Spontaneous / pathology. Neoplasms, Vascular Tissue / diagnosis. Skin Neoplasms / diagnosis

  • MedlinePlus Health Information. consumer health - Skin Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 10955689.001).
  • [ISSN] 0303-6987
  • [Journal-full-title] Journal of cutaneous pathology
  • [ISO-abbreviation] J. Cutan. Pathol.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] DENMARK
  •  go-up   go-down


21. Matter MJ, Gygi C, Gillet M, Gebhard S, Bouzourene H: Malacoplakia simulating organ invasion in a rectosigmoid adenocarcinoma: report of a case. Dis Colon Rectum; 2001 Sep;44(9):1371-5
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Malacoplakia is a histiocytic inflammatory response that may be associated with colorectal tumors.
  • He presented with a rectosigmoid tumor that seemed to infiltrate the urinary bladder and the sacrum on the preoperative CT scan and echography and at laparotomy.
  • A low anterior resection en bloc with a partial cystectomy was performed.
  • The pathologic analysis showed a pT3pN0 adenocarcinoma with an extensive malacoplakia infiltrating the bladder and the pericolic and perirectal tissues.
  • Our observation confirms the association of malacoplakia, colorectal carcinoma, and steroid treatment.
  • [MeSH-minor] Abdominal Pain / etiology. Aged. Diagnosis, Differential. False Positive Reactions. Humans. Inflammation. Lung Diseases / drug therapy. Male. Neoplasm Invasiveness. Neoplasm Staging. Steroids / therapeutic use

  • MedlinePlus Health Information. consumer health - Bladder Cancer.
  • MedlinePlus Health Information. consumer health - Colorectal Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 11584219.001).
  • [ISSN] 0012-3706
  • [Journal-full-title] Diseases of the colon and rectum
  • [ISO-abbreviation] Dis. Colon Rectum
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Steroids
  •  go-up   go-down


22. Van Es RJ, Baselmans AH, Koten JW, Van Dijk JE, Koole R, Den Otter W: Perilesional IL-2 treatment of a VX2 head-and-neck cancer model can induce a systemic anti-tumour activity. Anticancer Res; 2000 Nov-Dec;20(6B):4163-70
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Perilesional IL-2 treatment of a VX2 head-and-neck cancer model can induce a systemic anti-tumour activity.
  • A rabbit model with VX2 Squamous Cell Carcinoma transplanted into both auricles was used to test the effects of a regimen for local Interleukin 2 (IL-2) therapy, optimal in murine tumour models.
  • MATERIALS AND METHODS: Peri-tumoural IL-2 treatment started when one of the tumours exceeded 2 cm2 and consisted of 100,000 or 300,000 Chiron Units IL-2 or only solvent during 5 consecutive days.
  • The histology of the regressing tumours in cured cases showed an active granulomatous reaction with a histiocytic response, splitting up of tumour islands, and fibrinoid obstruction of blood vessels.
  • CONCLUSION: These findings showed local and systemic therapeutic effects of this local IL-2 regimen in a VX2 head-and-neck cancer model.
  • [MeSH-major] Antineoplastic Agents / pharmacology. Carcinoma, Squamous Cell / drug therapy. Head and Neck Neoplasms / drug therapy. Interleukin-2 / pharmacology
  • [MeSH-minor] Animals. Drug Screening Assays, Antitumor. Female. Lymphatic Metastasis / pathology. Neoplasm Transplantation. Rabbits. Remission Induction. Specific Pathogen-Free Organisms

  • MedlinePlus Health Information. consumer health - Head and Neck Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 11205243.001).
  • [ISSN] 0250-7005
  • [Journal-full-title] Anticancer research
  • [ISO-abbreviation] Anticancer Res.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Greece
  • [Chemical-registry-number] 0 / Antineoplastic Agents; 0 / Interleukin-2
  •  go-up   go-down


23. Hall RE, Agarwal S, Kestler DP: Induction of leukemia cell differentiation and apoptosis by recombinant P48, a modulin derived from Mycoplasma fermentans. Biochem Biophys Res Commun; 2000 Mar 5;269(1):284-9
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • We show that rP48-MBP induces differentiation of HL-60, U937 (human histiocytic lymphoma), and M1 (mouse myeloid leukemia) cell lines.
  • [MeSH-major] Apoptosis / drug effects. Bacterial Proteins / pharmacology. Cell Differentiation / drug effects. Cytokines / pharmacology. Leukemia / drug therapy. Leukemia / pathology. Membrane Proteins / pharmacology. Mycoplasma fermentans / chemistry
  • [MeSH-minor] Animals. HL-60 Cells. Humans. Macrophage-1 Antigen / metabolism. Mice. RNA, Messenger / genetics. RNA, Messenger / metabolism. RNA, Neoplasm / genetics. RNA, Neoplasm / metabolism. Recombinant Proteins / genetics. Recombinant Proteins / isolation & purification. Recombinant Proteins / pharmacology. Tumor Cells, Cultured. Tumor Necrosis Factor-alpha / genetics. U937 Cells

  • MedlinePlus Health Information. consumer health - Leukemia.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright 2000 Academic Press.
  • (PMID = 10694514.001).
  • [ISSN] 0006-291X
  • [Journal-full-title] Biochemical and biophysical research communications
  • [ISO-abbreviation] Biochem. Biophys. Res. Commun.
  • [Language] eng
  • [Grant] United States / NCI NIH HHS / CA / CA-58205; United States / NCI NIH HHS / CA / CA-72591
  • [Publication-type] Journal Article; Research Support, U.S. Gov't, P.H.S.
  • [Publication-country] UNITED STATES
  • [Chemical-registry-number] 0 / Bacterial Proteins; 0 / Cytokines; 0 / Macrophage-1 Antigen; 0 / Membrane Proteins; 0 / RNA, Messenger; 0 / RNA, Neoplasm; 0 / Recombinant Proteins; 0 / Tumor Necrosis Factor-alpha; 0 / polypeptide 48
  •  go-up   go-down


24. Baldus SE, Mönig SP, Schröder W, Metzger R, Lang S, Zirbes TK, Thiele J, Müller RP, Dienes HP, Hölscher AH, Schneider PM: [Regression of oesophageal carcinomas after neoadjuvant radiochemotherapy: criteria of the histopathological evaluation]. Pathologe; 2004 Nov;25(6):421-7
MedlinePlus Health Information. consumer health - Esophageal Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Following surgical resection locally advanced oesophageal carcinomas exhibit a bad prognosis and therefore neoadjuvant therapeutic strategies were developed.
  • Because success of therapy is associated with the extent of tumor regression in this context, the introduction of objective histopathological criteria seems to be very important.
  • This study included 67 patients with oesophageal carcinomas (cT2-cT4 cNx cM0) that were treated with a cisplatin- and 5-fluorouracil-containing simultaneous radiochemotherapy.
  • After completion of therapy, a surgical resection and a histopathological examination of the tissue specimens were performed.
  • The extent of tumor regression was histologically evaluated and therapy-induced alterations were graded semiquantitatively.
  • Additionally, the extent of a resorptive-histiocytic reaction, giant cells and lymphocytic infiltrates correlated with the grade of regression.
  • [MeSH-minor] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Carcinoma, Squamous Cell / drug therapy. Carcinoma, Squamous Cell / pathology. Carcinoma, Squamous Cell / radiotherapy. Carcinoma, Squamous Cell / surgery. Combined Modality Therapy. Female. Humans. Male. Middle Aged. Neoadjuvant Therapy. Neoplasm Staging. Treatment Outcome

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Curr Treat Options Oncol. 2002 Dec;3(6):475-85 [12392637.001]
  • [Cites] N Engl J Med. 1996 Aug 15;335(7):462-7 [8672151.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 2002 Feb 1;52(2):294-303 [11872273.001]
  • [Cites] Dis Esophagus. 2002;15(1):61-6 [12060045.001]
  • [Cites] Ann Surg Oncol. 2001 May;8(4):311-8 [11352304.001]
  • [Cites] Cancer. 1989 Sep 1;64(5):994-1001 [2474370.001]
  • [Cites] Cancer. 1999 Apr 1;85(7):1484-9 [10193937.001]
  • [Cites] Int J Oncol. 2002 Jun;20(6):1167-71 [12011994.001]
  • [Cites] Strahlenther Onkol. 2001 Jun;177(6):277-82 [11446315.001]
  • [Cites] Cancer. 1997 Sep 15;80(6):1011-20 [9305700.001]
  • [Cites] J Clin Pathol. 1993 Jan;46(1):51-5 [8432889.001]
  • [Cites] J Cancer Res Clin Oncol. 1997;123(9):469-77 [9341895.001]
  • [Cites] J Clin Oncol. 1999 Apr;17(4):1185 [10561177.001]
  • [Cites] J Clin Oncol. 2001 Jan 15;19(2):305-13 [11208820.001]
  • [Cites] Int J Colorectal Dis. 1997;12 (1):19-23 [9112145.001]
  • [Cites] Geburtshilfe Frauenheilkd. 1994 Oct;54(10):552-8 [8001751.001]
  • [Cites] Lancet. 2002 May 18;359(9319):1727-33 [12049861.001]
  • [Cites] Oncology. 2003;64(3):213-9 [12697960.001]
  • [Cites] Hepatogastroenterology. 1996 Sep-Oct;43(11):1260-72 [8908561.001]
  • [Cites] Br J Surg. 2000 Aug;87(8):1106-10 [10931059.001]
  • [Cites] Cancer. 1994 Jun 1;73(11):2680-6 [8194005.001]
  • [Cites] Cancer J. 2000 Apr;6 Suppl 2:S177-81 [10803833.001]
  • [Cites] G Chir. 1997 Oct;18(10):630-6 [9479977.001]
  • [Cites] Verh Dtsch Ges Pathol. 2000;84:164-74 [11217437.001]
  • [Cites] Pathologe. 1995 May;16(3):217-22 [7792274.001]
  • [Cites] Pathologe. 1997 Mar;18(2):131-40 [9244871.001]
  • [Cites] Chest. 2001 Nov;120(5):1584-91 [11713138.001]
  • (PMID = 15168076.001).
  • [ISSN] 0172-8113
  • [Journal-full-title] Der Pathologe
  • [ISO-abbreviation] Pathologe
  • [Language] ger
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] Germany
  •  go-up   go-down


25. Feldman AL, Minniti C, Santi M, Downing JR, Raffeld M, Jaffe ES: Histiocytic sarcoma after acute lymphoblastic leukaemia: a common clonal origin. Lancet Oncol; 2004 Apr;5(4):248-50
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Histiocytic sarcoma after acute lymphoblastic leukaemia: a common clonal origin.
  • [MeSH-major] Gene Rearrangement. Precursor Cell Lymphoblastic Leukemia-Lymphoma / drug therapy. Precursor Cell Lymphoblastic Leukemia-Lymphoma / genetics. Sarcoma / etiology. Sarcoma / genetics
  • [MeSH-minor] Adolescent. Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Clone Cells. DNA, Neoplasm / genetics. Humans. Male

  • MedlinePlus Health Information. consumer health - Soft Tissue Sarcoma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15050956.001).
  • [ISSN] 1470-2045
  • [Journal-full-title] The Lancet. Oncology
  • [ISO-abbreviation] Lancet Oncol.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] England
  • [Chemical-registry-number] 0 / DNA, Neoplasm
  •  go-up   go-down






Advertisement